A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
In this study, patients with BCC will be given neoadjuvant treatment with a drug called
sonidegib. Sonidegib is a daily tablet usually given for BCC that cannot be removed by
surgery or that has spread through the body. The study aims to see if sonidegib given for 12
weeks will reduce the size of tumours so surgery results in less scarring or may be avoided,
with only short term topical treatment required to treat remaining tumour.